Literature DB >> 1718855

Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice.

M Mihara1, Y Koishihara, H Fukui, K Yasukawa, Y Ohsugi.   

Abstract

Human interleukin-6 (hIL-6) injected into mice increases antigen-specific antibody production. In the present study, we examined the possibility that anti-hIL-6 murine monoclonal antibody (MH-166) could neutralize this hIL-6 activity in vivo. Although MH166 completely neutralized hIL-6 activity in vitro, treatment in vivo with hIL-6 and MH166 combined unexpectedly increased both anti-dinitrophenyl (DNP) and anti-sheep red blood cell (SRBC) antibody production more than treatment with IL-6 alone did. To explain this phenomenon, the serum hIL-6 level was monitored following the MH166 administration. The hIL-6 level was significantly higher in the mice treated with both hIL-6 and MH166 than in the mice treated with hIL-6 alone during the 24 hr following hIL-6 administration. These results indicate that MH166 prolongs half-life of a xenogeneic hIL-6.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718855      PMCID: PMC1384671     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

1.  Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6.

Authors:  M Mihara; H Fukui; Y Koishihara; M Saito; Y Ohsugi
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  Designing CD4 immunoadhesins for AIDS therapy.

Authors:  D J Capon; S M Chamow; J Mordenti; S A Marsters; T Gregory; H Mitsuya; R A Byrn; C Lucas; F M Wurm; J E Groopman
Journal:  Nature       Date:  1989-02-09       Impact factor: 49.962

3.  IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo.

Authors:  S Marinkovic; G P Jahreis; G G Wong; H Baumann
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

4.  Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

Authors:  T Hirano; T Taga; N Nakano; K Yasukawa; S Kashiwamura; K Shimizu; K Nakajima; K H Pyun; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

5.  The human bladder carcinoma line T-24 secretes a human B-cell differentiation factor.

Authors:  J F Christie; G Gallagher; W H Stimson
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

6.  Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo.

Authors:  F Takatsuki; A Okano; C Suzuki; R Chieda; Y Takahara; T Hirano; T Kishimoto; J Hamuro; Y Akiyama
Journal:  J Immunol       Date:  1988-11-01       Impact factor: 5.422

7.  Induction of rat acute-phase proteins by interleukin 6 in vivo.

Authors:  T Geiger; T Andus; J Klapproth; T Hirano; T Kishimoto; P C Heinrich
Journal:  Eur J Immunol       Date:  1988-05       Impact factor: 5.532

8.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

Authors:  M Kawano; T Hirano; T Matsuda; T Taga; Y Horii; K Iwato; H Asaoku; B Tang; O Tanabe; H Tanaka
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

9.  Recombinant human interleukin 6 (B cell stimulatory factor 2) enhances immunoglobulin secretion by single murine hapten-specific B cells in the absence of cell division.

Authors:  M R Alderson; B L Pike
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

10.  Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas.

Authors:  J Van Snick; S Cayphas; A Vink; C Uyttenhove; P G Coulie; M R Rubira; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

View more
  11 in total

1.  Antibody buffering of a ligand in vivo.

Authors:  Carol E O'Hear; Jefferson Foote
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-22       Impact factor: 11.205

2.  The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.

Authors:  Yuying Liu; Weihe Zhang; Lawrence H Cheung; Ting Niu; Qingping Wu; Chun Li; Carolyn S Van Pelt; Michael G Rosenblum
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

3.  A mathematical model for selective differentiation of neural progenitor cells on micropatterned polymer substrates.

Authors:  Cory L Howk; Howard A Levine; Michael W Smiley; Surya K Mallapragada; Marit Nilsen-Hamilton; Jisun Oh; Donald S Sakaguchi
Journal:  Math Biosci       Date:  2012-04-30       Impact factor: 2.144

4.  Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics.

Authors:  Weizao Chen; Yang Feng; Qi Zhao; Zhongyu Zhu; Dimiter S Dimitrov
Journal:  Mol Cancer Ther       Date:  2012-05-02       Impact factor: 6.261

5.  Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.

Authors:  H C van Zaanen; R P Koopmans; L A Aarden; H J Rensink; J M Stouthard; S O Warnaar; H M Lokhorst; M H van Oers
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

6.  An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.

Authors:  M G Rosenblum; L Cheung; K Mujoo; J L Murray
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

7.  Induction of autoimmune disease by graft-versus-host reaction across MHC class II difference: modification of the lesions in IL-6 transgenic mice.

Authors:  T Kimura; K Suzuki; S Inada; A Hayashi; H Saito; T Miyai; Y Ohsugi; Y Matsuzaki; N Tanaka; T Osuga
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

8.  Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation.

Authors:  K Gijbels; S Brocke; J S Abrams; L Steinman
Journal:  Mol Med       Date:  1995-11       Impact factor: 6.354

9.  Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody.

Authors:  Srinath Kasturirangan; G Jonah Rainey; Linda Xu; Xinwei Wang; Alyse Portnoff; Tracy Chen; Christine Fazenbaker; Helen Zhong; Jared Bee; Zhutian Zeng; Craig Jenne; Herren Wu; Changshou Gao
Journal:  J Biol Chem       Date:  2017-01-18       Impact factor: 5.157

10.  G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses.

Authors:  Mark P Rubinstein; Mohamed L Salem; Andrew L Doedens; Caitlin J Moore; Cody Chiuzan; Guillermo L Rivell; David J Cole; Ananda W Goldrath
Journal:  J Hematol Oncol       Date:  2013-10-01       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.